Amoxicillin And Clavulanate Potassium
NDC Package 70882-112-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Amoxicillin And Clavulanate Potassium is to reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Marketed by Cambridge Therapeutics Technologies, Llc, this product is identified by NDC 70882-112 and is authorized under FDA application ANDA065117.

Identification & Billing

NDC Package Code
70882-112-20
Package Description
20 TABLET, FILM COATED in 1 BLISTER PACK
Product Code
70882-112
11-Digit Billing Format
70882011220
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
20 EA
RxNorm Crosswalk
  • RxCUI: 617296 - amoxicillin 500 MG / clavulanate potassium 125 MG Oral Tablet
  • RxCUI: 617296 - amoxicillin 500 MG / clavulanate 125 MG Oral Tablet
  • RxCUI: 617296 - amoxicillin (as amoxicillin trihydrate) 500 MG / clavulanic acid (as clavulanate potassium) 125 MG Oral Tablet

Clinical Specifications

Proprietary Name
Amoxicillin And Clavulanate Potassium
Dosage Form
-
Usage Information
To reduce the development of drug‑resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium and other antibacterial drugs, amoxicillin and clavulanate potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Amoxicillin and clavulanate potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*:

Regulatory & Marketing

Labeler Name
Cambridge Therapeutics Technologies, Llc
FDA Application #
ANDA065117
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-27-2002
Listing Expiration
12-31-2019
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70882-112-20 identifies a specific commercial package of 20 tablet, film coated in 1 blister pack of Amoxicillin And Clavulanate Potassium, labeled by Cambridge Therapeutics Technologies, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Cambridge Therapeutics Technologies, Llc on November 27, 2002. The current certification is valid through December 31, 2019.

How is this Cambridge Therapeutics Technologies, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70882011220. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 20 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70882-112-20
11-Digit CMS (5-4-2)
70882-0112-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.